scispace - formally typeset
G

Glenn Salkeld

Researcher at University of Wollongong

Publications -  136
Citations -  7217

Glenn Salkeld is an academic researcher from University of Wollongong. The author has contributed to research in topics: Cost effectiveness & Health care. The author has an hindex of 43, co-authored 135 publications receiving 6770 citations. Previous affiliations of Glenn Salkeld include Sydney South West Area Health Service & University of North Carolina at Chapel Hill.

Papers
More filters
Journal ArticleDOI

Prospective Study of the Impact of Fear of Falling on Activities of Daily Living, SF-36 Scores, and Nursing Home Admission

TL;DR: Fear of falling has serious consequences for older people and interventions that successfully reduce fear of falling and improve fall-related self-efficacy are likely to have major health benefits.
Journal ArticleDOI

Quality of life related to fear of falling and hip fracture in older women: a time trade off study.

TL;DR: The utility (preference for health) associated with hip fracture and fear of falling among older women is estimated by finding the point at which respondents show no preference between a longer but lower quality of life and a shorter time in full health.
Journal ArticleDOI

Home visits by an occupational therapist for assessment and modification of environmental hazards: a randomized trial of falls prevention.

TL;DR: To determine whether occupational therapist home visits targeted at environmental hazards reduce the risk of falls, a large number of patients with a history of falls are referred to a therapist.
Journal ArticleDOI

Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study.

TL;DR: The high and largely preventable stroke/thromboembolism risk of those with newly identified AF highlights the likely benefits of community AF screening, and Guideline recommendation of community iECG AF screening should be considered.
Journal ArticleDOI

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

TL;DR: The World Health Organization is considering cost effectiveness in decisions about which drugs to make available for prescription.